After the explosive increase in the obesity market size led by GLP-1 agonist therapies in the last few years, the natural question is: what will biopharma’s next big growth markets be?
Scrip has interrogated Evaluate’s databases to provide a forecast of which segments will be the fastest growing for the 2024 to 2030 period, drawing on a range of sources to provide the
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?